Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions IIH - Idiopathic Intracranial Hypertensi...
Phase NA
Enrollment 80
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Background and study aims Idiopathic intracranial hypertension (IIH) is a neurological condition characterised by increased pressure inside the skull, called intracranial pressure (ICP). It is more common in women of reproductive age with obesity. Common symptoms of IIH include headaches, blurred vision and ringing in the ears. If left untreated, the disorder may cause blindness. The majority of patients with IIH are managed with weight loss and medications. Fewer than 10% of patients develop progressive visual loss and require urgent intervention to reduce ICP and preserve vision. This trial will compare the two most common interventions performed in the UK and evaluate their clinical and cost-effectiveness. The first is called cerebrospinal fluid (CSF) shunting and involves a procedure where a thin tube called a shunt is implanted in the body to drain brain fluid. The second is called dural venous sinus stenting (DVSS) and involves a procedure where a metallic mesh tube called a stent is implanted inside a brain blood vessel. Both procedures can preserve vision, but there is no strong evidence to support one over the other. Participants will have the same chance to be treated with CSF shunting or DVSS. The aim of the trial is to know which intervention is the most effective to save the vision and the most cost-effective. Who can participate? Adults with a diagnosis of IIH at risk of permanent sight loss What does the study involve? The trial will be conducted in NHS hospitals located in England, Wales and Scotland. Participants are randomly allocated to undergo cerebrospinal fluid (CSF) shunting or dural venous sinus stenting (DVSS). Afterwards the participants will be asked to attend 11 hospital appointments and one telephone appointment. This follow-up will take 2 years from start to finish. Participants will be closely monitored for any side effects and potential device failure, and for changes in vision, headaches and quality of life. The researchers will also collect health data from NHS Digital (the national custodian of NHS health and social care data). What are the possible benefits and risks of participating? There are no direct benefits from taking part in the trial but the information gained from this trial may help improve treatment for adults with IIH in the future. Participants may be seen more often and/or feel more supported as a consequence of their involvement in the trial. As with any intervention, there are risks and complications, but there are no additional disadvantages or risks involved in taking part in this trial. Both CSF shunting and stenting are treatments for IIH (shunting is widely used internationally, and in some hospitals, stenting is used as part of the standard of care). Participants require an intervention to prevent sight loss. None of these treatments is experimental but at present, there is not enough information to determine which treatment is most suitable and provides the higher level of health…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: CSF shunt — CSF shunt may be ventriculoperitoneal (VP) or lumboperitoneal (LP) at the discretion of the treating medical team.
  • Device: DVSS — Dural Venous Sinus Stent. Exact make and model of device not mandated by protocol.

Primary Outcomes

  • Global thickness of the retinal nerve fibre layer (RNFL) over 6 months, as measured by OCT (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-18
Completion: 2028-05-28
Eligibility
Age: 18 Years – 63 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Birmingham
Collaborators: National Institute for Health Research, United Kingdom
Contact Information
Study Contact:
Alexandra Sinclair, MBChB, FRCP, PhD
+44 121 414 8040
a.b.sinclair@bham.ac.uk
IIH Intervention Mailbox
+44 121 371 8107
iihintervention@trials.bham.ac.uk
Georgios Tsermoulas
The Queen Elizabeth Hospital
Interventions
  • Device: CSF shunt — CSF shunt may be ventriculoperitoneal (VP) or lumboperitoneal (LP) at the discretion of the treating medical team.
  • Device: DVSS — Dural Venous Sinus Stent. Exact make and model of device not mandated by protocol.
Study Locations (15 sites)
The Queen Elizabeth Hospital, Birmingham, United Kingdom
Bristol Eye Hospital, Bristol, United Kingdom
Southmead Hospital, Bristol, United Kingdom
Addenbrooke's Hospital, Cambridge, United Kingdom
University Hospital of Wales, Cardiff, United Kingdom
Princess Alexandra Eye Pavillion, Edinburgh, United Kingdom
Queen Elizabeth University Hospital, Glasgow, United Kingdom
Royal Hull Infirmary, Hull, United Kingdom
Leeds General Infirmary, Leeds, United Kingdom
King's College Hospital, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of IIH by the IIH consensus guidelines with papilloedema and at risk of visual loss. 2. Presence of papilloedema (Frisén grade ≥ 3) in at least one eye 3. Age 18 to \< 64 years at the time of consent. 4. Patients must be suitable for and willing to proceed with both CSF shunting (VP or Lumboperitoneal shunts only) and DVSS. 5. Able to provide written informed consent. Exclusion Criteria: 1. Presence of current venous sinus thrombosis on diagnostic brain imaging by either MRI, MRV or CTV 2. Previous surgery for IIH including, optic nerve sheath fenestration, CSF shunting procedures, sub-temporal decompression and DVSS. 3. Previous bariatric surgery within the last 3 months 4. Patients with a past ophthalmic history, except refraction error, affecting the eligible eyes (study eyes) that could affect the vision. 5. Patient is, at the time of signing the informed consent, a user of recreational or illicit drugs (including marijuana) or has had a recent history (within the last year) of drug or alcohol abuse or dependence, in the opinion of the investigator. 6. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. 7. Have participated in any other interventional study within 30 days prior to the screening visit (of note participation in the IIH Life database or other observational studies will not prevent enrolment to this study). 8. Previous randomisation for treatment in the present study. 9. Pregnant. 10. Absolute or serious contraindication to standard anti-thrombotic regimen peri and post stenting. 11. Secondary causes of raised intracranial pressure. (Refer to Protocol appendix 3 for additional information.) 12. History of significant documented iodine-based contrast allergy. 13. History of documented allergy to nitinol or nickel. 14. Absolute or serious contraindication for general anaesthesia. 15. Previous diagnosis of a hypercoagulable state (Factor V Leiden, Protein C or S deficiency, Anticardiolipin antibodies, Lupus anticoagulant, B2-glycoprotein-1 antibodies, or Hyperhomocysteinaemia). 16. Currently requiring full anticoagulation for other medical reasons, such as atrial fibrillation, artificial valves, deep vein thrombosis or pulmonary embolism. 17. Documented prior non-traumatic intracranial haemorrhage. 18. History of deep vein thrombosis or pulmonary embolism (within the last 24 months). 19. History of severe carotid atherosclerotic disease. 20. History of heart failure, dilated cardiomyopathy or congenital heart disease, etc. that are assessed as at high thrombotic risk. 21. Presence of intracranial vascular malformation considered clinically symptomatic (current or within 24 months). 22. Anatomical anomaly of the venous sinus which would prevent safe catheterisation and stenting (e.g. multi-channel sinus).
Conditions Hypertension, Pregnancy-Induced, HELLP S...
Phase Not Applicable
Enrollment 1106
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia is a serious high blood pressure condition that can develop during pregnancy. It is one of the leading causes of death and illness for mothers and babies in Africa. Doctors find it hard to tell which women with high blood pressure in pregnancy will go on to become seriously ill, because the tests available today are not accurate enough and are often not available in local clinics. Two proteins in the blood, called sFlt-1 and PlGF, may help predict who is at risk. The balance between them (the sFlt-1/PlGF ratio) has been useful in other parts of the world, but it has not been properly tested in African women. New rapid tests can measure these proteins at the clinic in minutes, using a small blood or urine sample, without a large laboratory. This study will look at how well these tests work in African women. Researchers will do two things. First, they will work out the result levels that best predict whether a woman will or will not develop severe preeclampsia in the following weeks, using a well-established laboratory test as the standard for comparison. Second, they will check how closely the rapid clinic tests match that laboratory standard. The study will also look at what these tests cost and whether using them could save money for families and health services. The study will include about 1,106 pregnant women at large maternity hospitals in Zimbabwe, Rwanda and Tanzania. Women may join if they are between 23 and 37 weeks pregnant with one baby and their care team suspects preeclampsia, for example because of raised blood pressure, protein in the urine, or symptoms such as headache, swelling or vision changes. Taking part does not change a woman's medical care in any way. Women will attend their usual pregnancy visits, plus study visits at 1 week, 2 weeks and 4 weeks, at delivery, and about 4 weeks after birth. At these visits the study team will record health information and collect blood and urine samples. About 15 ml of blood (around one tablespoon) is collected at each visit. The test results are not used to make any decisions about a woman's treatment. Doctors and nurses caring for her will not see them, and neither will she. All treatment decisions stay with her own healthcare team. Routine tests such as blood counts and liver tests are shared with her care team as usual. The results of this study may help clinics in Africa spot dangerous preeclampsia earlier, so mothers and babies can be treated in time.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Optimal sFlt-1/PlGF ratio cut-off values for predicting preeclampsia with severe features (derivation cohort) (Within 4 weeks after Visit 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-05
Completion: 2027-02-28
Eligibility
Age: 18 Years – 50 Years
Sex: FEMALE
Volunteers: false
Enrollment: 1106 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Africa Clinical Research Network (ACRN)
Contact Information
Study Contact:
Tariro Makadzange
+18572008374
tariro.makadzange@acrnhealth.com
Professor Chiratidzo Ndhlovu
+263772412701
rati.ndhlovu@acrnhealth.com
Mutala Trust
Interventions
N/A
Study Locations (1 sites)
Mutala Trust, Harare, Harare 263 Zimbabwe
Eligibility Criteria
Inclusion Criteria: * Gestational age between 23 weeks 0 days and 36 weeks 6 days, established by ultrasound performed at 22 weeks of gestation or earlier Singleton pregnancy Suspicion of a clinical diagnosis of preeclampsia based on one or more of the following: new onset of elevated blood pressure (systolic ≥130 mmHg or diastolic ≥80 mmHg); aggravation of pre-existing hypertension; new onset of protein in urine; aggravation of pre-existing proteinuria; or one or more other reasons for clinical suspicion of preeclampsia Other reasons for clinical suspicion include preeclampsia-related symptoms (epigastric pain, excessive oedema or severe swelling of the face, hands or feet, headache, visual disturbances, or sudden weight gain greater than 1 kg per week in the third trimester) or preeclampsia-related findings (low platelets, elevated liver transaminases, suspected intrauterine growth restriction, or abnormal uterine perfusion on Doppler sonography with mean pulsatility index above the 95th percentile in the second trimester and/or bilateral uterine artery notching, where available) Not currently enrolled in any other study or receiving an investigational medicinal product Able to provide informed consent Exclusion Criteria: * Multiple pregnancy (for example twins or triplets) Proteinuria 2+ or greater on dipstick AND elevated blood pressure (systolic ≥140 mmHg and/or diastolic ≥90 mmHg, reproducible on two occasions) Proteinuria 2+ or greater on dipstick and current antihypertensive treatment Confirmed diagnosis of HELLP syndrome No verified or documented ultrasound scan performed prior to 22 weeks of gestation to establish gestational age
Conditions Breast Cancer Stage I, Breast Cancer Sta...
Phase PHASE2
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are: 1. How breast cancer responds to endocrine therapy given prior to surgery? 2. To predict tumor pre-operative endocrine prognostic index (PEPI) score for subjects enrolled in cohort B or C Participants with early-stage breast cancer (Stage I-III) who are eligible for Neoadjuvant Endocrine Therapy (NET) will be enrolled in the study. Participants will: * receive endocrine therapy as part of regular care for breast cancer * consent to samples of blood and tissue evaluation to determine how endocrine therapy effects the tumor * participate in this research anywhere from 2 weeks to 1 year, depending on duration of endocrine therapy and when surgery will be performed

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Neoadjuvant endocrine therapy — Cohort A: Short duration NET. Patients in this cohort can be treated with NET up to 8weeks (\<= 8 weeks)
  • Drug: Neoadjuvant endocrine therapy — Cohort B: Intermediate duration NET. Patients in this cohort can be treated with NET \> 8weeks but \<=24 weeks
  • Drug: Neoadjuvant endocrine therapy — Cohort C: Extended duration NET. Patients in this cohort can be treated with NET \>24 weeks but \<= 52 weeks

Primary Outcomes

  • Response to neoadjuvant endocrine therapy (NET) (From enrollment to the end of treatment at <=52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-01
Completion: 2028-10
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: George Washington University
Contact Information
Study Contact:
Pavani Chalasani, MD
202-741-2277
pchalasani@mfa.gwu.edu
Richard Lush, PhD
202-994-0329
rmlush3@gwu.edu
George Washington-Medical Faculty Associates
Interventions
  • Drug: Neoadjuvant endocrine therapy — Cohort A: Short duration NET. Patients in this cohort can be treated with NET up to 8weeks (\<= 8 weeks)
  • Drug: Neoadjuvant endocrine therapy — Cohort B: Intermediate duration NET. Patients in this cohort can be treated with NET \> 8weeks but \<=24 weeks
  • Drug: Neoadjuvant endocrine therapy — Cohort C: Extended duration NET. Patients in this cohort can be treated with NET \>24 weeks but \<= 52 weeks
Study Locations (1 sites)
George Washington-Medical Faculty Associates, Washington D.C., District of Columbia 20037 United States
Eligibility Criteria
Inclusion Criteria: * Be capable of understanding the investigational nature of the study and all pertinent aspects of the study * Be capable of signing and providing written consent in accordance with institutional and federal guidelines * Histologically or cytologically confirmed diagnosis of invasive carcinoma of the breast * Clinical stage 1 to 3 breast cancer * Candidate for surgical resection * Estrogen receptor \> 10% positive stained cells based on most recent tumor biopsy and documented by a local laboratory or medical record. * HER2 negative or HER2 low breast cancer based on the most recent tumor biopsy and documented by a local laboratory or medical record. HER2 negative tumor is defined per American Society of Clinical Oncology and the College of American Pathologists guidelines, 2018. Patients with HER2 low tumors are eligible as long as patients are not candidates for any HER2 directed therapy. * Ability to take oral medication * Be willing and able to comply with scheduled visits, treatment plan, and follow up with research staff * Age ≥ 21 years Exclusion Criteria: * Inability to comply taking NET * Inability to comply to study procedures
Conditions Breast Cancer, Clinically Assessed Negat...
Phase NA
Enrollment 311
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The OMSLNB trial adopts a prospective, single-arm, non-inferiority, phase-II, open-label study design. Patients with unilateral invasive breast cancer (tumor ≤3cm) and assessed as cN0 will be eligible for inclusion, enrolled patients are required to complete 2 or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, eligible patients will avoid axillary surgery but will undergo breast surgery, which is not limited to breast-conserving surgery (BCS). So as to decrease the edema of upper arm, and finally improve the quality of life of the patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Omit SLNB — All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.

Primary Outcomes

  • invasive Disease-Free Survival (iDFS) (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-21
Completion: 2027-10-01
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 311 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Principal Investigators:
  • Xiaoming Zha, MD (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
Jue Wang, MD
025-68306360
wangjue200011@njmu.edu.cn
Xuan Li, MD
18154489540
lixuan1204@stu.njmu.edu.cn
Jue Wang, MD
025-68306360
wangjue200011@njmu.edu.cn
the First Affiliated Hospital of Nanjing Medical University
Interventions
  • Procedure: Omit SLNB — All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.
Study Locations (1 sites)
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-70 years; 2. Pathologically confirmed invasive breast cancer (regardless of pathological type) with a tumor diameter ≤ 3 cm, and planning to undergo breast surgery; 3. Negative axillary lymph nodes assessed by physical examination and imaging (2 or more of the following tests including ultrasound, breast MRI, breast PET-CT, breast PET-MRI, breast PET); 4. All patients are required to undergo immunohistochemical staining for Estrogen Receptor (ER), Progesterone Receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67 proliferation index, and further fluorescence in situ hybridization (FISH) should be performed in HER2 2+ cases; 5. Good compliance, normal comprehension and ability to receive treatment and follow-up as required; 6. ECOG score 0-1; 7. Patients volunteered for this study and signed the informed consent form. Exclusion Criteria: 1. Bilateral/lactating/pregnant breast cancer; 2. Previous history of malignant tumor or neoplasm; 3. Clinical or imaging confirmation of distant metastasis; 4. History of previous surgery on the affected axilla; or history of surgery affecting the function of the upper extremity; 5. Prior history of radiotherapy to the breast or chest; 6. Positive pathological margins after breast-conserving surgery or mastectomy; 7. Severe coagulation disorder, or a serious systemic disease, or an uncontrollable infection; 8. Aspartate aminortransferse (AST) and Alanine aminotransferase (ALT) ≥ 1.5 times the upper limit of normal, alkaline phosphatase ≥ 2.5 times the upper limit of normal, total bilirubin ≥ 1.5 times the upper limit of normal, serum creatinine ≥ 1.5 times the upper limit of normal; left ventricular injection fraction (LVEF) \< 50% on cardiac ultrasound; 9. Inability to complete the full course of follow-up adjuvant therapy as prescribed by the doctor for various reasons; 10. No personal freedom and independent civil capacity; 11. Presence of mental disorders, addictions, etc; 12. Not eligible for enrollmentas as judged by the investigator.
Conditions HER2-positive Breast Cancer
Phase PHASE1
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: [18F]FMISO PET/MRI imaging — \[18F\]FMISO PET/MRI imaging

Primary Outcomes

  • Baseline measure of PET standardized uptake value (SUV). (Baseline)
  • Baseline measure of apparent diffusion coefficient (ADC) in mm2/sec from MRI. (Baseline)
  • Baseline measure of signal enhancement ratio (SER) from MRI. (Baseline)
  • Changes in SER from MRI (Baseline through 6 months)
  • Changes in ADC from MRI (Baseline through 6 months)
  • Changes in SUV from PET (Baseline through 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-03-25
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Principal Investigators:
  • Jonathan McConathy, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Anna Sorace, PhD
205-934-3116
asorace@uabmc.edu
Sebastian Eady
2059962636
smeady@uabmc.edu
April Riddle, BSRT
205-934-6504
ariddle@uabmc.edu
The University of Alabama at Birmingham
Interventions
  • Drug: [18F]FMISO PET/MRI imaging — \[18F\]FMISO PET/MRI imaging
Study Locations (1 sites)
The University of Alabama at Birmingham, Birmingham, Alabama 35249 United States
Eligibility Criteria
Inclusion Criteria: 1. Patients must be ≥ 18 years old and ≤ 75 years old 2. HER2+ breast cancer determined on primary tumor by a local pathology laboratory and defined as IHC score 3+ and/or positive by ISH (defined by ISH ratio of ≥ 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies). Only one positive result is required for eligibility 3. Locally advanced stage II-III HER2+ breast cancer patients eligible for neoadjuvant therapy who are naïve to beginning treatment 4. Estimated life expectancy of greater than one year 5. Patients must have one lesion with RECIST measurable disease (great than 1 cm in diameter) Exclusion Criteria: 1. Inability to provide informed consent F 2. Weight over 350 lbs., due to the scanner bore size 3. Lactating, known or suspected pregnancy. Women with child-bearing potential must a have a negative serum β-hCG pregnancy test within 48 hours or a negative urine β-hCG pregnancy test within 48 hours of each PET imaging study. 4. Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) 5. Unable to lie still on the imaging table for one (1) hour 6. contraindication for gadolinium-based contrast agent, ProHance (gadoteridol)
Conditions Breast Cancer
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This research trial establishes a breast tumor tissue repository from core biopsies. Collecting breast tissue from core biopsies may allow doctors to learn more about the biology of breast cancer and to analyze proteins, genes, and other components of tumor cells. It may also allow doctors to conduct future studies to help understand how breast cancer grows and how it responds to different types of therapy. This will help doctors develop better breast cancer therapies and better tests to help make treatment decisions.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: cytology specimen collection procedure — Correlative studies

Primary Outcomes

  • Development of a baseline and serial breast cancer core biopsy repository within the USC/Norris Comprehensive Cancer Center Women's Cancer Program (Up to 10 years)
  • Development and maintenance of a secure clinical database of relevant demographic, clinical, pathologic, and longitudinal outcome characteristics of the samples to be banked (Up to 10 years)
  • Development of an efficient process for the distribution of de-identified samples from the bank to researchers with IRB-approved protocols or exemptions for the study of breast cancer-related questions (Up to 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2013-11-14
Completion: 2027-11-14
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Evanthia Roussos-Torres, M.D. (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Zeno Ashai
323-865-0463
zeno.ashai@med.usc.edu
Ameria Casillas-Lopez
323-865-0804
America.Casillas-Lopez@med.usc.edu
USC Norris Comprehensive Cancer Center
Julie Lang, M.D.
USC Norris Comprehensive Cancer Center
Interventions
  • Other: cytology specimen collection procedure — Correlative studies
Study Locations (1 sites)
USC Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Eligibility Criteria
Inclusion Criteria: * Known or suspected breast cancer * Known or suspected metastatic solid tumor that originated in the breast per the patient's medical history Exclusion Criteria: * Inability to sign informed consent * Known bleeding disorder * Use of anticoagulant medications (heparin, warfarin, etc.) within one week prior to biopsy * Use of antiplatelet medications (aspirin, clopidogrel, etc.) within one week prior to biopsy
Conditions Early-stage Breast Cancer, Estrogen-rece...
Phase PHASE2
Enrollment 112
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Procedure: Prospective data and sample collection — Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity, lifestyle questionaire
  • Drug: Ketorolac 10 Mg Oral Tablet — Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
  • Drug: Pregabalin 75mg — Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
  • Drug: Omeprazole 20mg Capsule — Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery

Primary Outcomes

  • To detect a reduced increase in systemic inflammation (from baseline to up to 24 hours after surgery) using peri-operative ketorolac (Up to 24 hours after surgery)
  • To detect a reduced increase in systemic neurotransmitters (from baseline to up to 24 hours after surgery) using peri-operative pregabalin (Up to 24 hours after surgery)
  • Change in biomarkers of metastasis at surgery from baseline (At surgery)
  • Change in tumoral immune cells recruitment at surgery from baseline (At surgery)
  • Change in tumoral neurogenesis at surgery from baseline (At surgery)
  • Change in tumoral neurotransmitters level at surgery from baseline (At surgery)
  • Change in Peripheral Blood Mononuclear Cells at surgery from baseline (At surgery)
  • Change in systemic neuro-inflammatory mediators at surgery from baseline (At surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-12
Completion: 2027-10
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 112 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jules Bordet Institute
Collaborators: KU Leuven
Principal Investigators:
  • Christine Desmedt, PhD (STUDY_CHAIR) - KU Leuven
  • Imane Bachir, MD (STUDY_CHAIR) - Jules Bordet Institute
Contact Information
Study Contact:
Imane Bachir, MD
+3225413601
imane.bachir@bordet.be
Marion Maetens, PhD
+3216321194
marion.maetens@kuleuven.be
Imane Bachir, MD
+322541
imane.bachir@hubruxelles.be
Institut Jules Bordet
Interventions
  • Procedure: Prospective data and sample collection — Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity, lifestyle questionaire
  • Drug: Ketorolac 10 Mg Oral Tablet — Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
  • Drug: Pregabalin 75mg — Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
  • Drug: Omeprazole 20mg Capsule — Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery
Study Locations (1 sites)
Institut Jules Bordet, Brussels, 1170 Belgium
Eligibility Criteria
Inclusion Criteria: Subjects must meet all of the following criteria in order to be eligible for this study: 1. Age ≥ 18 years and ≤ 70 years old 2. Female 3. Weight ≥ 35 kg 4. Histological diagnosis of invasive breast adenocarcinoma that is estrogen receptor positive as per the updated American Society of Clinical Oncology (ASCO) - College of American Pathologists (CAP) guidelines according to local testing with ER-positive is defined as having an immunohistochemistry (IHC) of 1% or more and/or Allred score of 3 or more 5. Tumour size ≥ 1.5 cm, determined by diagnostic ultrasound or MRI/CT scan. 6. Stage I, II or III disease (non-metastatic) 7. In case of multifocal, multicentric unilateral or bilateral breast: Adenocarcinoma tumours are allowed provided that all foci are ER+ according to local testing 8. Subject scheduled for a primary breast cancer surgery 9. Subject is willing to provide plasma/blood and tumour samples for translational research. 10. Subject is willing to provide tissue from a newly obtained core or excisional biopsy of the tumour that should be evaluable for central histological characterization and future molecular testing 11. Subject is willing to take omeprazole and has no contraindication to omeprazole. 12. Have an HEMSTOP score\<2 and conventional coagulation screening test within normal limits such as activated partial thromboplastin time (21.6\< aPTT \>28.7), international normalised ratio (1.31\<INR) and platelet count (\>100.10³/ml) 13. Women of childbearing potential must agree to use of one highly effective method of contraception prior study entry, during the course of the study and at least one months after the last administration of study treatment. 14. Negative serum pregnancy test for women of childbearing potential (within 30 days before start of treatment) 15. Subject is willing and able to provide written informed consent for the trial Exclusion Criteria: Subjects meeting one of the following criteria are not eligible for this study: 1. Subject planned for intraoperative radiotherapy 2. Subject planned for immediate reconstruction 3. Neoadjuvant BC therapy 4. Allergy to any NSAID or gabapentinoïd 5. Known hypersensitivity reactions to the investigational treatments, or any excipients or auxiliary medicinal products or concomitant medications. Hypersensitive to peanut or soya (related to propofol contraindications) 6. Current use of the antidiabetic agent thiazolidinedione (related to interaction with pregabalin), lithium salts, probenecid, pentoxifylline or intensive diuretic therapy. 7. Current NSAID (\> twice a week the year prior to diagnosis) or pregabalin use 8. Previous malignant pathology within 5 years prior to inclusion or currently undergoing maintenance therapy. Exceptions include basal cell carcinoma or squamous cell carcinoma of the skin that have undergone potentially curative therapy or in situ cervical cancer. 9. Active or history of peptic ulcer disease or gastro-intestinal bleeding or perforation 10. Pregnancy or lactating women 11. Chronic inflammatory disease as rheumatoid arthritis, uncontrolled asthma, chronic heart failure, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory myopathies (e.g., idiopathic polymyositis, dermatomyositis, inclusion body myositis), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), McArdle's disease, multiple sclerosis, lupus, chronic inflammatory demyelinating polyneuropathy, psoriasis, autoimmune thyroiditis as Graves' disease or Hashimoto's thyroiditis (unless previous surgical ablation), myasthenia gravis, vasculitis. 12. Complete or partial nasal polyposis syndrome, Quincke's oedema, bronchospasm, asthma 13. Known chronic infectious disease as active hepatitis B (defined as positive serology for Ac anti-HBc and IgM anti HBc OR Ac anti HBc and Ag HBs), active hepatitis C (defined as positive serology for anti-VHC and positive PCR-VHC) or active tuberculosis (included under treatment) 14. Uncontrolled HIV infection (defined as detectable viral loads by standard clinical assays) or controlled HIV infection (defined undetectable HIV viral loads by standard clinical assays) treated by one of following drugs: Nelfinavir, Atazanavir or Saquinavir (related to interaction with omeprazole). 15. Infection currently treated with one of the following drugs: posaconazole, voriconazole, ketoconazole and rifampicin, unless discontinuation of treatment is planned at least 10 days prior to the start of study treatment AND with complete resolution according to expert opinion (related to interaction with omeprazole) 16. Inadequate liver function (defined as total serum bilirubin ≥ 2 x upper limit of normal (ULN\<1.2 mg/dl) - unless documented Gilbert syndrome- AND Alanine Aminotransferase (ALT) ≥ 2 x ULN (ULN \<32 UI/l and ULN \<33 UI/l, respectively) AND Alkaline phosphatase (ALP) ≥ 2.5 x ULN (ULN=104 UI/l)) 17. Cirrhosis or severe hepatitis. 18. Renal impairment (defined as GFR\<90ml/min/1.73m² or serum creatinine \> 442 μmol/l or \> 5 mg/dL) or single kidney or previous renal surgery 19. Subject with history of (severe) renal toxicity with an NSAID 20. Subject with a recent history of operations associated with a high risk of bleeding 21. Previous, ongoing or suspected cardiovascular disease defined as history of ischemic heart disease or heart failure or uncontrolled high blood pressure (Systolic ≥160mmHg and/or diastolic ≥100mmHg) or peripheral arterial disease or cerebrovascular disease 22. Subject with a recent history of surgery associated with a high risk of bleeding 23. Hemostasis disorder as haemophilia, Von Willebrand disease, constitutional thrombopathies or thrombocytopenia (defined as platelet count \< 100 000/mm³), current /planned anticoagulant or anti-platelet therapy. 24. Inadequate bone marrow function (defined as absolute neutrophil count \<1000/μL and platelet count \<100'000/μL) 25. Systemic immunosuppressive treatment (defined as systemic corticotherapy or anti-rejection treatment or interferon therapy) within the 2-years prior diagnosis 26. Psychiatric disease or antipsychotic/ antidepressant use 27. Epilepsy or any current anti-epileptic drug use 28. Obstructive sleep apnea 29. ASA≥3
Conditions Breast Neoplasms
Phase PHASE2
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) is an antibody-conjugated drug. Results from the phase I safety, tolerability and pharmacokinetic trial of ARX788 single drug in Chinese patients with advanced HER2 breast cancer indicated a good safety of the test drug, and responses to anti-tumor therapy were observed in the target dose group. Phase II clinical trial is being carried out gradually. This trial is designed to observe the effectiveness and safety of pyrotinib maleate combined with ARX788 neoadjuvant treatment in stage II-III HER2-positive breast cancer patients experiencing a poor efficacy of trastuzumab and pertuzumab.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) — The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (\> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.

Primary Outcomes

  • Residual tumor burden (RCB) classification in grades (At least 3 years since enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-08-01
Completion: 2027-08-15
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shengjing Hospital
Principal Investigators:
  • Cai-Gang Liu (PRINCIPAL_INVESTIGATOR) - Department of Breast Surgery, Shengjing Hospital affiliated to China Medical University
Contact Information
Study Contact:
Nan Niu, MD
8618940256668
niunannancy@163.com
Nan Niu, MD
Shengjing Hospital affiliated to China Medical University
Cai-Gang Liu, MD
Shengjing Hospital affiliated to China Medical University
Interventions
  • Drug: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) — The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (\> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
Study Locations (1 sites)
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning 110004 China
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥ 18 but ≤ 75 years (The maximal age of the subjects enrolled in the Phase 3 study of pyrotinib is 75 years old, and there is no safety data for the use of the drug in older people); * Diagnosis of breast cancer meets the following criteria: Histologically confirmed invasive breast cancer; Tumor staging: Stage II-III patients who meet the 8th edition of AJCC Cancer Staging Manual; Patients who have undergone neoadjuvant therapy with trastuzumab and pertuzumab and have been assessed as SD (an increase of 0-20%), PD, inoperable or failing to meet the breast-conserving requirements; Failing to meet the breast-conserving requirements is defined as not meeting the following criteria: tumor size of T1 and T2 stage, proper breast volume, proper tumor-to-breast volume ratio, and able to maintain a good breast shape after surgery. * HER2-positive breast cancer pathologically confirmed is defined as Immunohistochemical method (IHC3+) or FISH+; * Eastern Cooperative Oncology Group (ECOG) level 0-1; * The functional level of major organs must conform to the following requirements: Neutrophils (ANC) ≥ 1.5×109/L (with no use of growth factors within 14 days); Platelet count (PLT) ≥ 100×109/L (with no correct treatment within 7 days ); Hemoglobin (Hb) ≥ 90 g/L (with no correct treatment within 7 days ); Total bilirubin (TBIL) ≤ 1.5×upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN; Urea nitrogen and creatinine ≤ 1.5×ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula); Cardiac color Doppler ultrasound: left ventricular ejection fraction (LVEF) ≥ 50%; 12-lead electrocardiogram: QT interval ≤ 480 ms; * Able to receive needle biopsy; * Patients who participate in the trial voluntarily, sign an informed consent, have good compliance and are willing to comply with the follow-up visit. Exclusion Criteria: * Patients who are concurrently receiving other anti-tumor therapy; * Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer; * With a history of any malignancies other than breast cancer in the past 5 years, excluding cured cervical carcinoma in situ, non-melanoma skin cancer or other malignant tumors; * Inability to swallow, chronic diarrhea and intestinal obstruction, and having many factors that affect drug administration and absorption; * Cardiac insufficiency, including but not limited to congestive heart failure, transmural myocardial infarction, angina pectoris requiring medical treatment, clinically significant valvular disease and high-risk arrhythmia, or abnormal QTc in the ECG examination during the screening period (at rest, QTc \> 450 ms in male or QTc \> 470 ms in female after correction of ECG examination); * Uncontrolled hypertension (at rest, systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg); * Patients who are suffering severe or uncontrolled systemic diseases, such as unstable or uncompensable respiratory, heart, liver, or kidney diseases, as per the investigator's judgments; * Female patients during pregnancy and lactation, or those who are fertile and positive for baseline pregnancy test or those of childbearing age who are unwilling to take effective contraceptive measures throughout the trial period; * Serious concomitant diseases or other comorbid diseases that will endanger the safety of patients or interfere with the completion of the trial, including but not limited to severe hypertension, severe diabetes mellitus, and active infections that are out of control; * Patients with known allergies to any active ingredients or excipients of ARX788, or with a history of protein drug allergy, a history of specific allergies (asthma, rheumatism, eczematous dermatitis), or a history of other severe allergic reactions, who are unsuitable for ARX788 treatment as per the investigator's judgments; * With a history of interstitial pulmonary disease, drug-induced pulmonary interstitial disease, and radiation pneumonitis that require hormone therapy, or any clinically active pulmonary interstitial disease as suggested by any evidence; * Patients who are currently suffering from keratitis, corneal disease, retinal disease, or active eye infection that require any interventions for the eyes.
Conditions Breast Cancer
Phase PHASE2
Enrollment 80
Locations 34 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Inavolisib — Participants will receive Inavolisib as per the schedule given in the protocol.
  • Drug: Fulvestrant — Participants will receive Fulvestrant as per the schedule given in the protocol.

Primary Outcomes

  • Percentage of Participants With Objective Response Rate (ORR) (Up to approximately 2 years)
  • Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) (Up to approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-02-18
Completion: 2031-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: WO46063 https://forpatients.roche.com/ No attachments to email below.
888-662-6728
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Drug: Inavolisib — Participants will receive Inavolisib as per the schedule given in the protocol.
  • Drug: Fulvestrant — Participants will receive Fulvestrant as per the schedule given in the protocol.
Study Locations (34 sites)
Los Angeles Cancer Network, Los Angeles, California 90017-4803 United States
Cancer Specialists of North Florida, Jacksonville, Florida 32256 United States
HCA Midwest Division, Kansas City, Missouri 64132 United States
Astera Cancer Care East Brunswick, East Brunswick, New Jersey 08816 United States
Instituto de Oncologia de Rosario, Rosario, Santa Fe Province S2000KPG Argentina
Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, C1426AGE Argentina
Hospital Privado - Centro Medico de Córdoba, Córdoba, 5016 Argentina
Centro Oncologico Riojano Integral (CORI), La Rioja, F5300COE Argentina
Hospital Provincial del Centenario, Rosario, S2002KDS Argentina
Centro Oncológico de Excelencia, San Juan, J5402BGA Argentina
Eligibility Criteria
Inclusion Criteria: * Documented ER +/ HER2- tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Disease progression after or during treatment with a combination of CDK4/6i and endocrine therapy: \<= 1 prior lines of systemic therapy in the locally advanced (recurrent or progressed) or metastatic setting * Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) * Participants for whom endocrine-based therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines * Confirmation of biomarker eligibility: presence of \>= 1 study-eligible PIK3CA mutation * Life expectancy of \> 6 months * Ability, in the investigator's judgment, and willingness to comply with all study -related procedures, including completion of patient-reported outcomes Exclusion Criteria: * Metaplastic breast cancer * Prior treatment with chemotherapy in the recurrent locally advanced/metastatic setting * Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes * Prior treatment with PI3K/Akt/mTOR inhibitors in the recurrent locally advanced/metastatic setting * Requirement for daily supplemental oxygen * Symptomatic active lung disease, including pneumonitis
Conditions Hormone Receptor Positive HER-2 Negative...
Phase PHASE2
Enrollment 176
Locations 36 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Trial design: Phase II, prospective, multi-center, randomized, open label, parallel group study in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutation, with 2:1 randomization into Arm A (olaparib + elacestrant) or arm B (olaparib). Treatment in either arm will be given until disease progression, unacceptable toxicity, withdrawal of patient´s consent to study participation, or end of study. Trial population: Patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutation, with an indication for standard-of-care PARP inhibitor therapy and planned treatment with olaparib, an ECOG performance status of 0-2 and life expectancy of \> 6 months, with normal bone marrow and kidney functions and no active or newly diagnosed central nervous system (CNS) metastases or symptomatic metastatic visceral disease at risk of life-threatening complications. Interventions: Patients randomized to Arm A will receive 600 mg olaparib daily and 400 mg elacestrant daily, while patients randomized to Arm B will receive 600 mg olaparib daily. Blood tests (hematology, biochemistry) will be performed at the beginning of every cycle, and imaging for tumor assessment (chest and abdominopelvic imaging) as well as QoL assessments will be performed every three months and in case of suspicion of progression/end of study.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Olaparib + Elacestrant — Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
  • Drug: Olaparib — Olaparib 600 mg orally daily

Primary Outcomes

  • Progression free survival (PFS) (PFS is defined as the time from randomization to first progression as assessed by the investigator, or death, whichever occurs first, assessed up to 48 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-13
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 176 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GBG Forschungs GmbH
Collaborators: Stemline Therapeutics, Inc.
Principal Investigators:
  • Sibylle Loibl, MD, PhD (STUDY_CHAIR) - Prof., MD ASCO, ESGO, ESMO, DKG, DGGG, AGO, DGS, BIG, BCIRG, St. Gallen Faculty Member, SABCS Faculty member
Contact Information
Study Contact:
Laura Steinmann
+49 61027480
element@gbg.de
Stefan Schoeffel
+49 61027480
element@gbg.de
Manfred Hofmann, PD Dr.
manfred.hofmann@vinzenz.de
Vinzenz Von Paul Kliniken gGmbH - Marienhospital
Interventions
  • Drug: Olaparib + Elacestrant — Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
  • Drug: Olaparib — Olaparib 600 mg orally daily
Study Locations (36 sites)
Vinzenz Von Paul Kliniken gGmbH - Marienhospital, Stuttgart, Baden-Wurttemberg Germany
University Hospital Tübingen, Tübingen, Baden-Wurttemberg 72076 Germany
Rems-Murr-Klinik-Winnenden, Winnenden, Baden-Wurttemberg Germany
GRN Klinik Weinheim, Weinheim, Baden-Württembergs 69469 Germany
Hämatologie-Onkologie im Zentrum MVZ GmbH, Augsburg, Bavaria 86150 Germany
Klinikum Bayreuth, Bayreuth, Bavaria Germany
Schwerpunktpraxis der Gynäkologie und Onkologie, Fürstenwalde, Brandenburg 15517 Germany
Agaplesion Frankfurter Diakonie Kliniken gGmbH, Frankfurt am Main, Hesse 60431 Germany
Klinikum der J. W. Goethe Universität, Frankfurt am Main, Hesse 60590 Germany
Klinikum Kassel GmbH - Frauenklinik, Kassel, Hesse 34125 Germany
Eligibility Criteria
Inclusion Criteria: Patients will be eligible for study participation only if they comply with the following criteria: 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for scheduled visit, the treatment and follow-up, must be obtained and documented according to the local regulatory requirements. 2. Female or male patients. 3. Age at study entry of at least 18 years. 4. Locally advanced or metastatic breast cancer that is HR-positive (ER and/or PgR ≥ 10% of stained cells at IHC) and HER2-negative (IHC 0 or 1+, or 2+ and ISH negative according to ASCO/CAP guidelines). 5. Patients with deleterious or suspected deleterious gBRCA1/2 mutation detected upon local testing. 6. Willingness and ability to provide archived formalin fixed paraffin embedded tissue (FFPE) block or a partial block from archived tumor or metastasis. 7. Indication for standard-of-care PARP inhibitor therapy and planned treatment with olaparib. 8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2. 9. Resolution of all acute toxic effects of prior anti-cancer therapy including endocrine therapy or surgical procedures to NCI CTCAE version 5.0 grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion). 10. Life-expectancy \> 6 months. 11. For female patients: patients of childbearing potential (defined as not post-menopausal and not permanently sterile \[latter defined as having undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy\]) require a negative serum or urinary pregnancy test within 72 hours before starting treatment in this study (in this case, patients need to use highly effective non-hormonal contraceptive methods as specified in the protocol). For male patients: during the intervention period and for at least 120 days after the last dose of elacestrant, patients should refrain from heterosexual intercourse or use a condom (and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak), and they should refrain from donating sperm. Exclusion Criteria: Patients will be ineligible for study participation if they fulfill any of the following criteria: 1. Known hypersensitivity reaction to one of the compounds, excipients, or substances used in this protocol. 2. Active or newly diagnosed CNS metastases, including leptomeningeal carcinomatosis, carcinomatous meningitis, or radiographic signs of CNS hemorrhage. Note: Patients with stable brain metastases are allowed. Radiotherapeutic treatment must be completed 1 week before planned day 1 of study therapy. 3. Presence of symptomatic metastatic visceral disease that are at risk of life-threatening complications in the short term, including but not confined to massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or fulminant liver involvement. 4. Inadequate organ function prior to enrolment including: * Hemoglobin \< 9 g/dL (\< 5.6 mmol/L) * Absolute neutrophil count (ANC) \< 1500/mm³ (\< 1.5 x 109/L) * Platelets \< 100,000/mm³ (\< 100 x 109/L) * Alanine aminotransferase (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) \> 3 x upper normal limits (ULN). If the patient has liver metastases, ALT and AST should not be ≥ 5 x ULN. * Alkaline phosphatase (ALP) \> 2.5 x ULN * Total serum bilirubin \> 1.5 x ULN (exception: patients with Gilbert's syndrome permitted up to ≤ 3 x ULN) * Serum creatinine \> 1.5 x ULN or estimated creatinine clearance \< 50 mL/min as calculated using the standard method for the institution. 5. Existing contraindication against the use of the elacestrant or olaparib. 6. Prior treatment with PARP inhibitors. 7. Female patients: pregnancy or lactation at the time of randomization or intention to become pregnant during the study and for a predefined period after the end of treatment (as described in protocol). Male patients: intention to get a child during the study and for a predefined period after the end of treatment (as described in protocol). According to the treatment received during the study, required contraception timelines for female and male patients are described in the study protocol. 8. Any of the following within 6 months prior to enrolment: myocardial infarction, severe/unstable angina, ongoing grade ≥ 2 cardiac dysrhythmias, prolonged QT corrected by Fridericia's formula (QTcF) grade ≥ 2, uncontrolled atrial fibrillation of any grade, coronary/peripheral artery bypass graft, heart failure of New York Heart Association (NYHA) Class II or greater, or cerebrovascular accident including transient ischemic attack. 9. Uncontrolled hypertension at the time of screening (systolic BP \> 140 mmHg or diastolic BP \> 90 mmHg that has not been adequately treated or controlled). 10. Active and current anticoagulation for treatment purposes of thrombotic events occurring \< 6 months before enrolment is not allowed (prophylactic anticoagulation, however, is acceptable). Treatment with an anticoagulant for a thrombotic event occurring \> 6 months before enrolment, or for an otherwise stable and allowed medical condition (e.g., well controlled atrial fibrillation) is acceptable, provided dose and coagulation parameters (as defined by local standard of care) are stable for at least 28 days prior to the first dose of study drug. 11. Known difficulty in tolerating oral medications or conditions which would impair absorption of oral medications such as: uncontrolled nausea or vomiting (i.e., CTCAE ≥ grade 3 despite antiemetic therapy), ongoing gastrointestinal obstruction/motility disorder, malabsorption syndrome, or prior gastric bypass. 12. History of endometrial intraepithelial neoplasia in patients who have not undergone a hysterectomy. 13. Malignant disease other than breast cancer, active or being disease-free for less than 5 years (except carcinoma in situ of the cervix, DCIS, and non-melanomatous skin cancer adequately treated). 14. Uncontrolled significant active infections including HBV, HCV, and/or HIV. Patients with a positive hepatitis B surface antigen result or a positive hepatitis C antibody test result at screening or within 3 months before first dose of study treatment are excluded, except for the following: * Participants with positive anti-HBs antibody titer and confirmatory negative hepatitis B DNA polymerase chain reaction. * Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if they have both completed curative therapy and have a hepatitis C viral load \< quantifiable limit. 15. Any severe, acute, uncontrolled, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational or non-investigational products administration, or may interfere with the interpretation of study results, and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. Moreover, patients who, by virtue of an order issued by judicial or administrative authorities, are committed to an institution or those who cannot take part in clinical trials are excluded from this study. 16. History of significant neurological or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent. 17. Unable or unwilling to avoid medications, supplements (e.g., St. John's wort), or foods (e.g., grapefruit, pomegranate, pomelos, star fruit, Seville oranges and their juices) that are moderate/strong inhibitors or inducers of CYP3A4 activity. Participation will be allowed if the medication, supplements, or foods are discontinued for at least 14 days prior to study entry and for the duration of the study. 18. Concurrent treatment with other experimental
Conditions Breast Neoplasm Female
Phase PHASE4
Enrollment 50
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Paclitaxel — Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.

Primary Outcomes

  • Response to Paclitaxel (Up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2017-03-13
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Wisconsin, Madison
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Marina Sharifi, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Wisconsin, Madison
Contact Information
Study Contact:
Cancer Connect
800-622-8922
clinicaltrials@cancer.wisc.edu
Mark Burkard, MD, PhD
University of Iowa Health Care/Holden Comprehensive Cancer Center
Cancer Connect
800-622-8922
clinicaltrials@cancer.wisc.edu
University of Wisconsin Carbone Cancer Center
Interventions
  • Drug: Paclitaxel — Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
Study Locations (2 sites)
University of Iowa Health Care/Holden Comprehensive Cancer Center, Iowa City, Iowa 52242 United States
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53792 United States
Eligibility Criteria
Inclusion Criteria: * Women with pathologically demonstrated breast cancer * Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist. No other investigational or commercial therapeutic agents may be given concurrently with the paclitaxel. * Patients must not have metastatic disease on staging work-up per institutional guidelines. * A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from a prior biopsy of the primary tumor (preferred) or lymph node. A minimum of 8 slides must be available. * The primary tumor or lymph node must be readily biopsied by surgery or radiology teams. * The primary tumor must be measurable by an imaging modality prior to treatment. This imaging modality is to be repeated after completion of 4 cycles of paclitaxel and prior to surgery. Such imaging modalities may include ultrasound, CT, mammography, or MRI. MRI will be the preferred imaging modality if available because it has the highest accuracy and positive predictive value for predicting pathologic complete response.All imaging will be performed per standard of care at the discretion of the treating physicians. * Subjects may not have had prior systemic chemotherapy regimens administered for treatment of their current breast cancer. However, studies (window studies, for example) that are deemed non-therapeutic, including those that utilize agents that are not FDA approved for the treatment of the patient's current breast cancer, are permitted. * Patients must have adequate organ and marrow function as determined by the treating oncologist. * Patient must be willing to undergo additional biopsy of breast tumor or lymph node. * Patient must have the ability and willingness to sign a written informed consent document. * Women of childbearing potential (per institutional policy) must agree to use effective contraception as discussed with treating oncologist for the duration of the study. Exclusion Criteria: * History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel including to other drugs formulated in Cremophor(R) EL (polyoxyethylated castor oil). * Patients with known HIV due to concern that chemotherapy may cause further immunosuppression and potential infectious complications. * Patients on non-aspirin anti-coagulation (Coumadin, heparins, or clopidogrel) or with documented bleeding disorders will be excluded due to risk of bleeding with biopsy. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, other malignancies requiring therapy or psychiatric illness/social situations that would limit compliance with study requirements as determined by treatment physician. * Pregnant women are excluded from this study because paclitaxel is a pregnancy category D drug and may cause deleterious effects to the fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with paclitaxel, breastfeeding should be discontinued if the mother is enrolled in the trial.
Conditions HR+/HER2- Breast Cancer, HR+, HER2-, Adv...
Phase PHASE1, PHASE2
Enrollment 380
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: AVZO-021 — AVZO-021 is an oral selective CDK2 inhibitor
  • Drug: Fulvestrant — Antineoplastic agent, estrogen receptor antagonist
  • Drug: Letrozole — Antineoplastic agent, aromatase inhibitor
  • Drug: AVZO-023 — AVZO-023 is an oral selective CDK4 inhibitor

Primary Outcomes

  • Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1) (Cycle 1 (28 Days))
  • Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1) (From baseline until end of study treatment or study completion (approximately 2 years))
  • Determine the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) (Phase 1) (Approximately 16 months)
  • Objective Response Rate (ORR) (Phase 2) (From baseline through disease progression or study completion (approximately 2 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-08-20
Completion: 2030-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 380 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Avenzo Therapeutics, Inc.
Contact Information
Study Contact:
Medical Information
(858) 239-2944
ClinicalTrials@avenzotx.com
Avenzo Therapeutics
Avenzo Therapeutics Recruiting Site
Avenzo Therapeutics
Avenzo Therapeutics Recruiting Site
Interventions
  • Drug: AVZO-021 — AVZO-021 is an oral selective CDK2 inhibitor
  • Drug: Fulvestrant — Antineoplastic agent, estrogen receptor antagonist
  • Drug: Letrozole — Antineoplastic agent, aromatase inhibitor
  • Drug: AVZO-023 — AVZO-023 is an oral selective CDK4 inhibitor
Study Locations (16 sites)
Avenzo Therapeutics Recruiting Site, Los Angeles, California 90025 United States
Avenzo Therapeutics Recruiting Site, Los Angeles, California 90095 United States
Avenzo Therapeutics Recruiting Site, New Haven, Connecticut 06519 United States
Avenzo Therapeutics Recruiting Site, Orlando, Florida 32827 United States
Avenzo Therapeutics Recruiting Site, Sarasota, Florida 34232 United States
Avenzo Therapeutics Recruiting Site, Tampa, Florida 33612 United States
Avenzo Therapeutics Recruiting Site, Boston, Massachusetts 02215 United States
Avenzo Therapeutics Recruiting Site, New York, New York 10016 United States
Avenzo Therapeutics Recruiting Site, Cleveland, Ohio 44106 United States
Avenzo Therapeutics Recruiting Site, Columbus, Ohio 43221 United States
Eligibility Criteria
Key Inclusion Criteria: * Male or female aged ≥ 18 years old at screening with Eastern Cooperative Oncology Group (ECOG) 0-1 and life expectancy \> 3 months * Patients with histologically or cytologically proven advanced malignancies of preferred indications * Measurable disease (as assessed by investigator using RECIST v1.1) is preferred in Phase 1 dose escalation, unless otherwise specified in the protocol, and in all patients in Phase 2. Bone only disease is allowed in dose escalation. * Agree to provide molecular test report results to confirm eligibility and archival tumor samples and/or fresh biopsy, as applicable * Adequate renal, liver, and bone marrow function Key Exclusion Criteria: * Patients should not have received any prior selective investigational CDK (CDK2, CDK4, CDK2/4, CDK2/4/6) inhibitors * Has known active brain metastasis (have either previously untreated intracranial CNS metastasis or previously treated intracranial central nervous system (CNS) metastasis with radiologically documented new or progressing CNS lesions) or leptomeningeal disease * Other concurrent invasive malignancy or a prior invasive malignancy for which treatment was completed within 3 years before the first dose on study except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ, or colorectal adenomatous polyps * Last anticancer treatment within 2 weeks (4 weeks for biologic, immunotherapy or ADC) or 5 half-lives of the drug, whichever is shorter, prior to first dose on study * Major surgery within 4 weeks prior to first dose on study * Have received radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment, except for patients receiving whole brain radiotherapy, which must be completed at least 4 weeks prior to the first dose of study treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have active radiation pneumonitis. Patients who received radiation of \>25% of bone marrow are excluded. * Strong or moderate CYP3A4 inhibitors or inducers within 2 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose on study * History of serious cardiovascular conditions within 6 months prior to first dose on study * Unresolved toxicities from prior therapy greater than Grade 1 (per CTCAE version 5.0) (with exceptions of alopecia, vitiligo, and ≤ Grade 2 peripheral neuropathy) prior to the first dose on study * History of drug-induced pneumonitis/interstitial lung disease * Confirmed loss of function mutation or deletion of Rb1 gene * Previous high-dose chemotherapy requiring stem cell rescue